MedTrace Logo

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

NCT07024147 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-17

No results posted yet for this study

Summary

JWCAR239 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR239 in patients with B Cell Non-Hodgkin Lymphoma (B-NHL)

Conditions

  • B-Cell Non-Hodgkin Lymphoma
  • Large B Cell Diffuse Lymphoma
  • Follicular Lymphoma
  • Marginal Zone B Cell Lymphoma
  • Mantle Cell Lymphoma (MCL)

Interventions

BIOLOGICAL

JWCAR239

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells targeting CD19/CD20

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Sponsors & Collaborators

  • Shanghai JW Therapeutics Co., Ltd.

    collaborator UNKNOWN

  • Peking University Cancer Hospital & Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2027-07-01
Completion
2030-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07024147 on ClinicalTrials.gov